Aster DM Healthcare acquires 45.09 million shares in Aster DM Super‑Specialty (Sarjapur) via rights issue

What Aster DM Healthcare announced

On 18 June 2026, Aster DM Healthcare Ltd filed a Regulation 30 (LODR) announcement with the BSE stating that it has acquired 4,50,89,995 equity shares of Rs 10 each in its wholly‑owned subsidiary, Aster DM Super‑Specialty (Sarjapur) Private Limited. The acquisition was executed through a rights issue offered to existing shareholders of the subsidiary.

Details of the rights issue

The rights issue involved the issuance of 4,50,89,995 shares at a face value of Rs 10 per share. While the filing does not disclose the premium, if any, the nominal capital raised by the subsidiary amounts to Rs 450.9 crore (face value only). The rights were subscribed by Aster DM Healthcare, effectively increasing its equity stake in the Sarjapur entity.

"The Company has acquired 4,50,89,995 equity shares of Rs. 10/- each through rights issue in Aster DM Super‑Specialty (Sarjapur) Private Limited."

No further financial terms, such as issue premium, use of proceeds, or impact on the parent’s balance sheet, were disclosed in the announcement.

Key facts at a glance

Why this matters for investors

The subscription increases Aster DM Healthcare’s equity holding in its Sarjapur super‑specialty arm, potentially strengthening the parent’s control over the subsidiary’s operations and future earnings. Since the transaction was carried out via a rights issue, the capital raised is internal to the group and does not dilute the listed shareholders of Aster DM Healthcare. However, the parent’s cash outflow (or financing arrangement) to fund the subscription is not disclosed, leaving the exact impact on its liquidity unclear.

Conclusion

Aster DM Healthcare has completed a rights‑issue subscription for 45.09 million shares in its Sarjapur super‑specialty subsidiary, amounting to a nominal Rs 450.9 crore. The filing provides limited financial detail, and while the move consolidates the parent’s stake, the broader implications for the group’s balance sheet remain to be clarified in future disclosures.